1. Introduction {#sec1-genes-11-00277}
===============

Mutations in genes that encode transporter proteins in the renal tubule alter kidney capacity to maintain homeostasis and cause diseases recognized under the generic name of inherited tubulopathies. Hereditary tubulopathies constitute a heterogeneous group of rare diseases with a global prevalence that is still difficult to estimate. Although by combining genetic and functional studies, we have reached a better understanding of the mechanisms of these disorders, and the genetic cause for a significant number of affected patients is still unknown. This may derive from the variable clinical picture, overlapping phenotypes, insufficient exploration of the genome, mostly of non-coding areas, or incomplete knowledge about the genes governing renal tubular function.

Next-generation sequencing (NGS) has become increasingly accessible for both research and clinical practice and brought new challenges into the interpretation process \[[@B1-genes-11-00277],[@B2-genes-11-00277],[@B3-genes-11-00277]\]. Some of the challenges associated with it are derived from the technology itself (a higher number of variants in genes other than the gene of interest, incidental discoveries eliciting ethical issues, hard to sequence genomic regions) \[[@B1-genes-11-00277],[@B4-genes-11-00277]\]. Other challenges are related to the limited information available to interpret the variants. Genetic heterogeneity, pleiotropy, variable penetrance, and expressivity, overlapping phenotypes, at least during the early stages, may influence interpretation. Bartter and Gitelman syndromes represent the best examples in this respect \[[@B5-genes-11-00277],[@B6-genes-11-00277],[@B7-genes-11-00277]\]. Occasionally, acquired disorders can mimic genetic tubulopathies (for example, a Gitelman-like syndrome as a rare consequence of Sjögren syndrome) and thus initiate a diagnostic odyssey for the patient. In this article, we aim to highlight the most frequent and recent challenges and controversies raised by the genetic diagnosis of inherited tubulopathies.

2. Exploring the Genetic Causes of Tubulopathies {#sec2-genes-11-00277}
================================================

The evolution of genetic technologies has facilitated the discovery of a large number of disease genes, initially starting with the identification of a candidate gene based on its linkage with certain markers transmitted with the disease in affected families (positional cloning). Sanger sequencing was introduced in 1977 \[[@B8-genes-11-00277]\] and has supported gene discovery and diagnosis for more than four decades. Human genes vary in length from several hundreds to a few million base pairs \[[@B9-genes-11-00277]\], which makes Sanger sequencing a very inefficient method for mutation detection in large genes or sets of genes. It is still used in clinical practice to validate results obtained through faster, high-throughput methods. Next-generation sequencing of whole or targeted exomes or even whole genomes circumvented issues like the partial overlap of certain phenotypes and the genetic heterogeneity \[[@B10-genes-11-00277],[@B11-genes-11-00277],[@B12-genes-11-00277]\]. This progress was accompanied by the discovery of a subset of variants that can be difficult to interpret with current knowledge \[[@B13-genes-11-00277],[@B14-genes-11-00277],[@B15-genes-11-00277]\]. To safeguard the accuracy of genetic diagnosis, guidelines for variant interpretation have been developed and published by the American College of Medical Genetics \[[@B16-genes-11-00277]\]. These recommendations proved to be very useful in clinical context, when variants in validated genes are investigated. An initial evaluation of how different labs apply these criteria showed substantial disagreement \[[@B17-genes-11-00277]\], but following subsequent discussions led to an improved consistency \[[@B18-genes-11-00277],[@B19-genes-11-00277]\]. However, when new genes or new inheritance patterns are discovered, these guidelines are insufficient. Experimental evidence has shown that the physicochemical nature of an amino acid change, conservation through multiple species, and the rarity of the variant are not always indicative of pathogenicity \[[@B20-genes-11-00277],[@B21-genes-11-00277],[@B22-genes-11-00277]\]. Once large-scale sequencing became available and the results collected into large populational datasets like Exome Aggregation Consortium (ExAc) \[[@B23-genes-11-00277]\] and Genome Aggregation Database (gnomAD) \[[@B24-genes-11-00277]\], some of the variants previously considered to be causal for a rare disease have been re-classified as uncertain significance or non-pathogenic \[[@B21-genes-11-00277],[@B25-genes-11-00277]\] after being found in large numbers in the control population.

3. Animal Models Do Not Always Reflect Human Disease {#sec3-genes-11-00277}
====================================================

One aspect impeding a better understanding of the changes of renal physiology induced by mutations in genes responsible for tubular transport is the inconsistent reproduction of the phenotype in animal models \[[@B26-genes-11-00277]\]. For example, the mouse expressing *GATM* (Glycine Amidinotransferase) mutants causing AD renal Fanconi syndrome did not show any aminoaciduria or glucosuria \[[@B27-genes-11-00277]\]. This is also dependent on the type of genetic modification: (a) knock-out mouse reproducing the effect of a loss-of-function variant is the most used model; (b) knock-in mouse obtained by editing the gene to include the precise pathogenic variant identified in patients. A knock-in experiment introducing the missense *WNK4* (WNK Lysine Deficient Protein Kinase 4) mutation p.(Q562E) identified the pathogenic mechanism resulting in pseudohypoaldosteronism type II in humans and a similar phenotype in mice \[[@B28-genes-11-00277]\]. In the case of *SLC34A1* (Solute Carrier Family 34 Member 1), two mouse models of Slc34a1 deficiency either due to genetic deletion or to the spontaneous occurrence of the compound heterozygous mutations at p.(L499V) and p.(V528M) show no Fanconi syndrome \[[@B29-genes-11-00277],[@B30-genes-11-00277]\]. However, a mouse bearing two Slc34a1 missense mutations presented electrolytic abnormalities due to a trafficking defect \[[@B30-genes-11-00277],[@B31-genes-11-00277]\]. OCRL (Inositol Polyphosphate-5-Phosphatase) KO mice did not exhibit Lowe syndrome/Dent disease unless Inpp5b (Inositol Polyphosphate-5-Phosphatase B) was deleted in the proximal tubule as well. This is due to the specific redundancy of Ocrl and Inpp5b in mice which required a deletion of either both genes or replacement of Inpp5b with the human gene to obtain similar phenotype to the one observed in Lowe patients \[[@B32-genes-11-00277]\]. The zebrafish model has impaired endocytosis, but normal cilia function \[[@B33-genes-11-00277]\]. *SLC26A1* (Solute Carrier Family 26 Member 1) is an anion exchanger with expression in a limited number of tissues (liver, gut, and kidney). The KO mice exhibit hyposulfatemia, hypersulfaturia, calcium oxalate urolithiasis, and nephrocalcinosis \[[@B34-genes-11-00277]\]. In addition, they have an increased sensitivity to acetaminophen, which is a significant aspect for pharmacogenetics studies in humans \[[@B34-genes-11-00277]\]. The differences between humans and mice or other animal models challenge our capacity to document the functional effects of genetic variants.

4. Large-Scale Sequencing Projects Have Variable Diagnostic Yields {#sec4-genes-11-00277}
==================================================================

Two large multicentre studies identified a mutation in 70% of the children \[[@B7-genes-11-00277]\] and about 26% in adults \[[@B6-genes-11-00277]\] with clinically diagnosed tubulopathies. Another study found a genetic diagnosis in 7% of 235 Pakistani patients diagnosed with nephrolithiasis \[[@B35-genes-11-00277]\]. Braun et al. found a monogenic cause of nephrolithiasis (NL) or nephrocalcinosis in close to 17% \[[@B36-genes-11-00277]\] of the patients, in which the recessive mutations were more frequent than the autosomal dominant. This proportion is similar to another study that included both children and adults with NL \[[@B37-genes-11-00277]\]. Smaller scale projects were dedicated to distal renal tubular acidosis (dRTA) \[[@B38-genes-11-00277]\], Dent disease \[[@B39-genes-11-00277],[@B40-genes-11-00277]\], and Gitelman syndrome \[[@B41-genes-11-00277]\] providing genetic confirmation of the diagnosis in variable proportions. The high number of cases with an unresolved genetic diagnosis can be explained by the complex nature of tubulopathies, with both genetic and environmental factors contributing to the disease, as well as the limited knowledge about the contribution of other genes, the small number of patients with some very rare conditions and phenotype variability. The number of studied genes differed in each case. An internationally reviewed resource, PanelApp, attempts to gather expert knowledge to support inclusion of new genes and a permanent review of known genes as part of gene panels for molecular diagnosis \[[@B42-genes-11-00277]\]. The tubulopathy panel contains 57 genes of which 38 are validated with high confidence (<https://panelapp.genomicsengland.co.uk/panels/292/>; accessed 27/02/2020) according to the number of cases, functional studies supporting causality and other supporting evidence. Two genes, HNF4A (Hepatocyte Nuclear Factor 4 Alpha) and SLC2A2 (Solute Carrier Family 2 Member 2) causing renal Fanconi syndrome 4 and Fanconi-Bickel syndrome, respectively, are not yet classified due to the reduced number of cases published so far. The panel can be exported and used for selecting genes to be analyzed.

5. Genetic and Phenotypic Heterogeneity Complicate Genetic Analysis {#sec5-genes-11-00277}
===================================================================

Genetic heterogeneity and variations in phenotype are probably the biggest challenges in the genetic diagnosis of renal tubulopathies, and this is illustrated by [Table 1](#genes-11-00277-t001){ref-type="table"} containing the genes associated with inherited tubulopathies and the corresponding phenotypes described for each gene.

Fanconi renotubular syndrome (FRTS) is one of the best examples of genetic heterogeneity and phenotype variation. The renal Fanconi syndrome may be inherited or secondary to nephrotoxic substances, autoimmune diseases, or cancer \[[@B43-genes-11-00277]\]. Four entities have been clustered so far under the name of renal Fanconi syndrome, three autosomal dominant and one autosomal recessive \[[@B44-genes-11-00277],[@B45-genes-11-00277]\]. The renal phenotype is the result of impaired reabsorption in the proximal tubule, resulting in loss of water, phosphate, glucose, bicarbonate (HCO3-), uric acid, aminoacids, and low molecular weight proteins \[[@B43-genes-11-00277]\]. The patients present with polyuria and polydipsia, impaired growth, rickets and osteopenia; in time, they may develop renal insufficiency \[[@B43-genes-11-00277],[@B46-genes-11-00277]\]. Three forms (FRTS1, FRTS3, and FRTS4) are validated and follow an autosomal dominant (AD) inheritance pattern while the fourth (FRTS2), which is autosomal recessive, is still debated due to the limited number of cases and insufficient experimental evidence. In addition, a number of other multisystemic, metabolic inherited disorders may associate with renal Fanconi syndrome: cystinosis, galactosemia, hereditary fructose intolerance, tyrosinemia, Wilson disease, and mitochondrial diseases, reviewed in \[[@B43-genes-11-00277],[@B47-genes-11-00277]\]. This heterogeneity adds to the fact that sometimes the full clinical picture develops in time, thus delaying appropriate management and increasing the risk of renal failure \[[@B48-genes-11-00277]\]. Therefore, the early diagnosis is a challenge for the clinician and requires a broad molecular investigation.

FRTS1 was initially linked to a different location at 15q15.3 by Lichter-Konecki et al. \[[@B50-genes-11-00277]\], but the gene could be identified only after re-analysis of the data extending the region to include the flanking markers and thus the *GATM* gene \[[@B27-genes-11-00277]\]. The mutations impair mitochondrial clearance by generating long polymers that prevent mitochondrial fission and degradation \[[@B27-genes-11-00277]\] in the renal proximal tubules. *GATM* encodes for L-arginine:glycine amidino-transferase, an enzyme whose gene product was originally isolated from pig kidney mitochondria \[[@B51-genes-11-00277]\]. Interestingly, biallelic nonsense mutations had been described as the cause for cerebral creatine deficiency syndrome 3 (OMIM\# 612718) with autosomal recessive inheritance \[[@B52-genes-11-00277],[@B53-genes-11-00277]\] and without any documented renal phenotype.

FRTS3 is caused by monoallelic mutations in the *EHHADH* gene (enoyl-CoA hydratase/3-hydroxyacyl CoA dehydrogenase), an enzyme involved in peroxisomal oxidation of fatty acids \[[@B49-genes-11-00277]\]. The phenotype had been described in 1955 by Luder at al. \[[@B54-genes-11-00277]\] and Tolaymat et al. \[[@B55-genes-11-00277]\] and it is reviewed in \[[@B47-genes-11-00277]\].

FRTS4 \[[@B56-genes-11-00277]\] has been identified by Hamilton et al.; in patients displaying both features of mature onset diabetes of young (MODY) and proximal renal tubulopathy associating nephrocalcinosis, hypercalciuria and hypermagnesemia, hypocalcemia, and renal impairment. The neonates with this condition have hyperinsulinism and increased birth weight.

More controversies surround the association between mutations in *SLC34A1* and autosomal recessive FRTS, type 2 \[[@B45-genes-11-00277]\]. A biallelic in-frame duplication of 21 bp found in two children from a consanguineous family leads to complete loss of function due to a defective membrane localisation of the mutated protein \[[@B45-genes-11-00277]\]. No further cases have been published and thus OMIM considered this gene-phenotype association as provisional, in concordance with PanelApp \[[@B42-genes-11-00277]\], which maintains this association in the "Red" zone. *SLC34A1* encodes for the NaPiIIa transporter which contributes by about 70--80% of the apical influx of sodium and phosphate, thus being the major effector of phosphate reabsorption in the kidney \[[@B57-genes-11-00277]\]. Phosphate is mostly reabsorbed in the proximal tubule, and there is no known secretion along the tubule. Reduced systemic phosphate determines adaptive changes with suppression of *FGF23* (Fibroblast Growth Factor 23), increased 1-alpha hydroxylation of vitamin D, and suppressed PTH, mobilisation of calcium and phosphate from bones and increased calcium deposits in kidneys (nephrocalcinosis). Mutations in *SLC34A1* are also causal for AR infantile hypercalcemia \[[@B58-genes-11-00277],[@B59-genes-11-00277],[@B60-genes-11-00277]\], with many cases reported in the literature. Conversely, it was proposed by some \[[@B35-genes-11-00277],[@B61-genes-11-00277],[@B62-genes-11-00277],[@B63-genes-11-00277]\] and contested by others \[[@B64-genes-11-00277],[@B65-genes-11-00277],[@B66-genes-11-00277]\] that monoallelic mutations in the same gene determine AD hypophosphatemia and nephrocalcinosis, particularly in association with environmental factors. A dominant negative effect of heterozygous NaPiIIa mutations could not be demonstrated and phosphate transport has been mildly affected in some of the experiments \[[@B64-genes-11-00277],[@B66-genes-11-00277]\]. In all cases, the proposed disease mechanism is a classical loss-of-function, with mostly point mutations (missense, splicing, nonsense, frameshift) identified. Two mutations, p.(I456N) and p.(R512C), were shown to impair trafficking to the membrane \[[@B63-genes-11-00277]\]. SLC34A1 deficiency seems to have a higher impact at earlier ages, while in adulthood the phenotype becomes milder \[[@B57-genes-11-00277]\]. *SLC34A1* mutations have been found in five cases of infantile hypercalcemia of a total of 410 children with tubulopathies underlining the rarity of this condition \[[@B7-genes-11-00277]\]. A similar study focusing on 1033 adult patients identified only two patients with renal hypophosphatemia and heterozygous variants in *SLC34A1* \[[@B6-genes-11-00277]\]. It is accepted that SlC34A1 is characterised by an increased number of single allele non-synonymous variants in the general population, with increased predisposition to developing kidney stones \[[@B67-genes-11-00277],[@B68-genes-11-00277]\] and chronic kidney disease \[[@B69-genes-11-00277],[@B70-genes-11-00277]\].

*SLC34A3* (Solute Carrier Family 34 Member 3) is another member of the SLC34 gene family expressed in the proximal tubule which contributes less to phosphate reabsorption and has been associated with AR hypophosphatemic rickets with hypercalciuria (HHRH) \[[@B71-genes-11-00277],[@B72-genes-11-00277]\]. In this case, both recessive and dominant inheritance are largely accepted, following the discovery that heterozygotes have been seen in a number of cases with hypercalciuria and kidney stones but without bone disease and with inconsistent hypophosphatemia \[[@B73-genes-11-00277]\]. One of the mutations, p.(Ser192Leu), is more frequent among Europeans and associated with a less severe renal and osseous phenotype in homozygous form \[[@B74-genes-11-00277]\] and with increased predisposition to renal calcification (NL/NC) when heterozygous \[[@B68-genes-11-00277],[@B75-genes-11-00277]\]. Experimental studies demonstrated a reduced phosphate transport function of the mutant channel in different cellular systems (*Xenopus* oocytes and Human embryonic kidney cells, HEK293) and the high frequency in gnomAD database (99 alleles out of a total of 214,524; 88 of 91,194 alleles in Europeans) interpreted in the context of a milder phenotype \[[@B74-genes-11-00277]\]. Similar experiments were not able to support any evidence of functional impairment in monoallelic cases \[[@B74-genes-11-00277]\]. Both transporter proteins may adjust their cell surface expression in accordance with hormonal factors and phosphate intake \[[@B76-genes-11-00277]\]. Missense mutations can prevent proper localisation of the protein at the membrane \[[@B77-genes-11-00277]\]. Carriers of some *SLC34A3* mutations may present with hypercalciuria \[[@B71-genes-11-00277]\], but a functional study of two carriers in a family of a HHRH patient showed no biochemical abnormality \[[@B77-genes-11-00277]\]. In fact, both *SLC34A1* and *SLC34A3* are known to harbor a large number of monoallelic variants, as shown by control populational databases \[[@B57-genes-11-00277]\].

Another gene involved in phosphate reabsorption is *SLC20A2* (Solute Carrier Family 20 Member 2), but, unlike the *SLC34A1* and *SLC34A3*, it is expressed ubiquitously and the associated phenotype involves brain calcifications but no renal features \[[@B78-genes-11-00277]\]. *XPR1* is a gene presumed to be expressed in the basolateral membrane, where it might export phosphate into the blood stream \[[@B79-genes-11-00277]\]. There is no renal disease associated with mutations in this gene, despite the kidney being one of the organs with higher expression; instead, several missense mutations have been reported to cause a form of basal ganglia calcification \[[@B80-genes-11-00277]\]. Although no pathogenic variants associated with a renal phenotype have been identified in humans, the mouse in which Xpr1 gene had been conditionally inactivated exhibited a clear picture of renal tubular dysfunction \[[@B81-genes-11-00277]\]. A better understanding of these genes and more detailed experimental studies may shed light on the intricate physiology of the proximal tubule.

6. Mutations outside the Known Pattern for the Condition {#sec6-genes-11-00277}
========================================================

Variation in some genes like *SLC5A2*, *AQP2*, *KLHL3*, *SLC4A1*, or *SLC2A9* may follow either an autosomal recessive or autosomal dominant pattern, with one of these being the rule while the other is occasionally seen. The disease mechanism might differ between AD and AR even for those cases where the phenotype is similar \[[@B82-genes-11-00277]\]. This is not unique to tubulopathies and raises a challenge for the clinical interpretation of new variants that are not yet experimentally proven to be pathogenic. Experiments with either heterozygous, homozygous, or compound heterozygous knock-in models may orient the interpretation, and the new genome-editing technologies and organoid models are expected to clarify many of the questions we still have today \[[@B83-genes-11-00277]\]. In most cases, the disease mechanism is of loss-of-function in both AD and AR cases but also gain-of-function is seen in some of the AD conditions \[[@B82-genes-11-00277]\]. Thus, autosomal dominant *SLC5A2* is caused by a reduced transport function, to about 70% of the wild-type level \[[@B84-genes-11-00277]\]. Variants in *KLHL3* cause Pseudohypoaldosteronism type IID in either monoallelic (AD) or biallelic (AR) combinations. The difference is that the variants causing AD disease are clustered at intra- or intermolecular interaction sites, impeding functional interactions \[[@B85-genes-11-00277]\]. AD NDI-causing *AQP2* mutations are located towards the C-terminal end and exert a dominant-negative effect \[[@B86-genes-11-00277]\]. The same clustering and disease mechanism is seen in *SLC4A1* \[[@B87-genes-11-00277]\], while a loss-of-function mechanism has been found for *SLC2A9* \[[@B88-genes-11-00277]\].

Deep intronic mutations may escape detection, unless suspected and investigated separately or within a more general, whole-genome approach. They have been cited in *SLC34A3* \[[@B89-genes-11-00277],[@B90-genes-11-00277]\], or *SLC12A3* \[[@B91-genes-11-00277],[@B92-genes-11-00277]\]. Since targeted panel sequencing is the commonest approach, these rare cases might be missed unless supplementary tests are performed. Regularly, the introns are considered the less conserved parts of a gene, where most variations may accumulate without significant consequences, unless they change one of the critical regions, the canonical donor and acceptor sites or the branch site. However, occasionally, some of these variants disrupt regulatory regions or other genes, introduce a new, ectopic splice site, resulting in an insertion of a new sequence (pseudo-exon) that can be in-frame or shift the reading frame and ultimately lead to insertion of a premature stop codon \[[@B93-genes-11-00277]\]. Deep intronic mutations are reported in more than 77 disease-associated genes \[[@B93-genes-11-00277]\]. The *SLC5A2* gene encodes for the major sodium-glucose cotransporter in the kidney \[[@B94-genes-11-00277]\]. Monoallelic and biallelic mutations are responsible for isolated renal glycosuria \[[@B95-genes-11-00277],[@B96-genes-11-00277],[@B97-genes-11-00277]\]. Besides several missense and truncating mutations, an intronic variant consisting of a deletion of 20 nucleotides between −10 and −31, presumably affecting the branching site, has been published \[[@B98-genes-11-00277]\]. As whole genome sequencing becomes more cost-efficient and broadly used, it is expected that the number of reported mutations in this category will increase.

Occasionally, a tubulopathy gene may be affected as part of a contiguous gene deletion and lead to a syndromic presentation. An example is a deletion comprising *SLC34A1* and *NSD1* determining the association of severe hypophosphatemia to Sotos syndrome \[[@B99-genes-11-00277]\]. Therefore, once any sign of renal tubular impairment is seen in a patient, it is worth exploring potential additional causes as this can be critical for disease management and genetic counselling in the family.

A recent international survey identified 6 out of 36 patients with no clear causative variant in any of the known dRTA genes as being heterozygous for the variant ATP6V1B1: c.1181G\>T, p.(Arg394Gln). Since the second pathogenic variant has not been identified in these cases \[[@B100-genes-11-00277]\] as well as others \[[@B7-genes-11-00277],[@B101-genes-11-00277]\], it has been suggested that this mutation might be an example of autosomal dominant inheritance, but this still needs experimental proof.

A heterozygous mutation (c.265G\>A; p.(A89T)) added glycosuria to the phenotype of an otherwise unrelated disease, juvenile cataract with microcornea, caused by monoallelic *SLC16A12* mutations. Because *SLC16A12* was found to be also expressed in the kidney, the association had been initially reported as a new syndrome \[[@B102-genes-11-00277],[@B103-genes-11-00277]\]. Further segregation studies demonstrated that glucosuria was a separate phenotype \[[@B104-genes-11-00277]\]. Thus, a broader genetic investigation in the case of an unusual presentation of a disorder is more appropriate to clarify the diagnosis and guide management and family counselling as the occurrence of two independent genetic disorders, however exceptional, must not be disregarded.

7. Digenic Inheritance {#sec7-genes-11-00277}
======================

Mutations in more than one gene may exceptionally be associated with an unusual phenotype \[[@B105-genes-11-00277]\]. With replacement of single gene sequencing by whole exome or whole genome sequencing, it is likely that many more such cases will surface where pathogenic variants are found in two or more genes, suggesting the so-called digenic or oligogenic inheritance. One question that might be asked in such situations is whether this is a true digenic effect \[[@B106-genes-11-00277]\] or the second gene bears a mutation only by chance. In diseases with variable phenotype like renal tubulopathies, this is more difficult to assess. It is known that some genes are more tolerant to non-synonymous variation \[[@B107-genes-11-00277]\]. A number of renal transporters can be included in this category: *SLC34A1* is already a famous example, acknowledged by many publications and the allelic frequency in populational databases.

According to the cases reported so far in tubulopathies and in other conditions, several situations can be recognized: (1) two genes causing similar phenotypes are mutated simultaneously according to the recognised individual pattern and generate a more severe or variable phenotype \[[@B108-genes-11-00277]\]; (2) two genes from the same pathway and with known functional and/or physical overlap suffer from inactivating mutations with a different phenotype \[[@B109-genes-11-00277]\]; and (3) variants in two or more genes, inconsistent with the pattern of inheritance characteristic for the disease \[[@B110-genes-11-00277],[@B111-genes-11-00277]\].

Bartter and Gitelman syndromes are the commonest renal tubulopathies \[[@B5-genes-11-00277],[@B112-genes-11-00277]\]. Clinical and biochemical characteristics are detailed here \[[@B5-genes-11-00277]\]. There are five main forms of Bartter syndrome, each with an independent genetic cause and a subset of characteristic biochemical features \[[@B5-genes-11-00277]\]. Clinical presentation is not always suggestive and may not be similar in all affected members in a family. Expert consensus guidelines \[[@B112-genes-11-00277]\] have been drawn up to guide efficient genetic testing in GS patients. One interesting and challenging aspect is the number of digenic inheritance reports following the initial case of Bartter syndrome and deafness caused by inactivating biallelic mutations in both *CLCNKA* and *CLCNKB* \[[@B109-genes-11-00277],[@B113-genes-11-00277]\]. The patient presented with a similar phenotype to Bartter syndrome 4A, known to be caused by mutations in *BSND* \[[@B114-genes-11-00277]\]. More recently, next-generation sequencing results suggested more cases of digenic inheritance in Bartter and Gitelman syndromes, one of which involves monoallelic variants in *CLCNKB* and *SLC12A3* genes \[[@B111-genes-11-00277]\]. There is no demonstrated dominant negative effect of a heterozygous *CLCNKB* or *SLC12A3* mutation and no experiment has proven that in heterozygous state these variants would have any effect at all on protein stability, trafficking, or transport function. Carrier relatives of patients with either *CLCNKB* or *SLC12A3* associated Gitelman syndrome are healthy. The two chloride channels, CLCNKA and CLCNKB, are known to interact and to be co-expressed in certain parts of the nephron and internal ear. They both require BSND for stability and membrane localisation \[[@B115-genes-11-00277]\]. In the ascending loop of Henle, *CLCNKA* is less expressed, which means that inactivating mutations in *CLCNKB* result in salt loss and impaired mineral homeostasis as a result of reduced chloride export from the renal tubule cells \[[@B116-genes-11-00277],[@B117-genes-11-00277]\]. Through inactivating mutations of both genes, there is a severe loss of saline transport associated with hearing loss due to defective formation of endolymph \[[@B113-genes-11-00277]\]. This phenotype is similar to that generated by mutations in *BSND*, thus illustrating the interdependence of the three genes \[[@B114-genes-11-00277]\]. Interestingly, only homozygous inactivating mutations in each of the two chloride channels, *CLCNKA* and *CLCNKB*, have been associated with deafness, perfectly overlapping with the definition of true digenic effects. Digenic inheritance requires a demonstrable interaction between the two genes, a clear consistence across a larger pedigree or multiple pedigrees \[[@B105-genes-11-00277]\], which could be proven for Bartter syndrome 4B but would be less convincing in other cases. Exome and genome sequencing result in a larger number of potentially damaging variants, which make them more demanding in terms of analysis and interpretation. Similar results have been reported in dRTA \[[@B118-genes-11-00277]\].

A patient with Dent 2 disease was found to have mutations in both *CLCN5* and *OCRL* genes, and an intermediary phenotype between DD and LS \[[@B108-genes-11-00277]\], while another case with *OCRL* and *INPP5B* variants presented with a Chiari I malformation \[[@B119-genes-11-00277]\].

Given the number of non-synonymous mutation in the genes encoding for transporter proteins, it is very likely that pathogenic mutations can be present independently in more than one gene thus requiring a thorough experimental, genetic, and physiological investigation before supporting a non-canonical inheritance pattern. Interestingly, some of the genes associated with Mendelian diseases are also the site of relatively rare variants that confer increased susceptibility to common forms of renal diseases (nephrolithiasis, chronic kidney disease) \[[@B120-genes-11-00277],[@B121-genes-11-00277],[@B122-genes-11-00277]\].

While the occurrence of damaging variants in two or more genes in one individual is not impossible, we can suggest that these cases must be validated experimentally before being used to manage and counsel patients and families.

8. Conclusions {#sec8-genes-11-00277}
==============

Next-generation sequencing has the potential to speed up gene discovery and thus improve management of patients with inherited tubulopathies through a more precise molecular diagnosis. One effect of the technology can be generation of a large list of variants of unknown significance that can lead to overinterpretation and false diagnostic association, unless stringent criteria are applied to classify and interpret them.
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###### 

Genes associated with inherited tubulopathies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene                                                                              Alias                                                Official Name                                                                 OMIM      Associated Phenotype                                                                OMIM     Inheritance1
  --------------------------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------------------------------- --------- ----------------------------------------------------------------------------------- -------- -----------------------------------
  **Proximal tubule \*\***                                                                                                                                                                                                                                                                                                    

  **GATM**                                                                          AGAT                                                 Glycine amidinotransferase                                                    602360    Cerebral creatine deficiency syndrome 3                                             612718   AR

  Renal Fanconi syndrome and kidney failure                                                                                              AD                                                                                                                                                                                   

  EHHADH                                                                            LBFP; LBP                                            Enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase                       607037    Fanconi renotubular syndrome 3                                                      615605   AD

  HNF4A                                                                             TCF14, HNF4                                          Hepatocyte nuclear factor 4-alpha                                             600281    Fanconi renotubular syndrome 4, with maturity-onset diabetes of the young           616026   AD

  MODY, type I                                                                      125850                                               AD                                                                                                                                                                                   

  SLC2A2                                                                            GLUT2                                                Solute carrier family 2 (facilitated glucose transporter), member 2           138160    Fanconi-Bickel syndrome                                                             227810   AR

  **SLC22A12**                                                                      URAT1, OAT4L                                         Solute carrier family 22 (urate transporter), member 12                       607096    Hypouricemia                                                                        220150   AR

  **SLC2A9**                                                                        GLUT9                                                Solute carrier family 2 (facilitated glucose transporter), member 9           606142    Hypouricemia, renal, 2                                                              612076   AR, AD

  **REN**                                                                           RENIN                                                Renin                                                                         179820    Hyperuricemic nephropathy, familial juvenile 2                                      613092   AD

  Renal tubular dysgenesis                                                          267430                                               AR                                                                                                                                                                                   

  CLCN5 \*                                                                          CHLORIDE CHANNEL, VOLTAGE-GATED, K2; CLCK2; CLC5     Chloride voltage-gated channel 5                                              300008    Dent disease                                                                        300009   XLR

  Hypophosphatemic rickets                                                          300554                                               XLR                                                                                                                                                                                  

  Nephrolithiasis, type I                                                           310468                                               XLR                                                                                                                                                                                  

  Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis           308990                                               XLR                                                                                                                                                                                  

  OCRL \*                                                                           OCRL1                                                OCRL, inositol polyphosphate-5-phosphatase                                    300535    Dent disease 2                                                                      300555   XLR

                                                                                    Lowe syndrome                                        309000                                                                        XLR                                                                                                    

  **KCNJ10**                                                                        GLIAL INWARDLY RECTIFYING POTASSIUM CHANNEL Kir4.1   Potassium voltage-gated channel subfamily J member 10                         602208    Enlarged vestibular aqueduct, digenic                                               600791   AR

  EAST/SESAME syndrome                                                              612780                                               AR                                                                                                                                                                                   

  **SLC5A2**                                                                        SGLT2                                                Solute carrier family 5 (sodium/glucose cotransporter), member 2              182381    Renal glucosuria                                                                    233100   AR, AD

  ABCG2                                                                             ABCP BCRP MRX                                        ATP binding cassette subfamily G member 2                                     603756    \[Junior (Jr) blood group system\]                                                  614490   

  \[Uric acid concentration, serum, QTL1\]                                          138900                                               ?AD                                                                                                                                                                                  

  SLC9A3R1 \*                                                                       NHERF1\                                              Solute carrier family 9, MEMBER 3, regulator 1                                604990    Nephrolithiasis/osteoporosis, hypophosphatemic, 2                                   612287   AD
                                                                                    EBP50                                                                                                                                                                                                                                     

  XPR1                                                                              SLC53A1, SYG1                                        Xenotropic and polytropic retrovirus receptor                                 605237    Basal ganglia calcification, idiopathic, 6                                          616413   AD

  **FAH**                                                                           FUMARYLACETOACETASE                                  Fumarylacetoacetate hydrolase                                                 613871    Tyrosinemia, type I                                                                 276700   AR

  **CTNS**                                                                          CYSTINOSIN                                           Cystinosin, lysosomal cystine transporter                                     6060272   Cystinosis, atypical nephropathic                                                   219800   AR

  Cystinosis, late-onset juvenile or adolescent nephropathic                        219900                                               AR                                                                                                                                                                                   

  Cystinosis, nephropathic                                                          219800                                               AR                                                                                                                                                                                   

  Cystinosis, ocular nonnephropathic                                                219750                                               AR                                                                                                                                                                                   

  **Thick ascending loop of Henle (TAL) and Distal Convoluted Tubule (DCT) \*\***                                                                                                                                                                                                                                             

  **SLC12A1**                                                                       NKCC2                                                Solute carrier family 12 (sodium/potassium/chloride transporter), member 1    600839    Bartter syndrome, type 1                                                            601678   AR

  **KCNJ1**                                                                         ROMK; ROMK1, KIR1.1                                  Potassium voltage-gated channel subfamily J member 1                          600359    Bartter syndrome, type 2                                                            241200   AR

  **CLCNKB**                                                                        CLCKB                                                Chloride voltage-gated channel Kb                                             602023    Bartter syndrome, type 3                                                            607364   AR

  Bartter syndrome, type 4b, digenic                                                613090                                               DR                                                                                                                                                                                   

  **BSND**                                                                          BARTTIN                                              Barttin CLCNK type accessory beta subunit                                     606412    Bartter syndrome, type 4a                                                           602522   AR

  CLCNKA                                                                            CLCK1                                                Chloride voltage-gated channel Ka                                             602024    Bartter syndrome, type 4b, digenic                                                  613090   DR

  **MAGED2**                                                                        MELANOMA ANTIGEN, FAMILY D, 2;                       MAGE family member D2                                                         300470    Bartter syndrome, type 5, antenatal, transient                                      300971   XLR

  **SLC12A3**                                                                       NCC, NCCT                                            Solute carrier family 12 (sodium/chloride transporter), member 3              600968    Gitelman syndrome                                                                   263800   AR

  **TRPM6**                                                                         CHAK2;                                               Transient receptor potential cation channel subfamily M member 6              607009    Hypomagnesemia 1, intestinal                                                        602014   AR

  FXYD2                                                                             ATP1G1                                               FXYD domain containing ion transport regulator 2                              601814    Hypomagnesemia 2, renal                                                             154020   AD

  **CLDN16**                                                                        PCLN1                                                Claudin 16                                                                    603959    Hypomagnesemia 3, renal                                                             248250   AR

  EGF                                                                               UROGASTRONE; URG                                     Epidermal growth factor                                                       131530    Hypomagnesemia 4, renal                                                             611718   AR

  **CLDN19**                                                                        CLAUDIN 19                                           Claudin 19                                                                    610036    Hypomagnesemia 5, renal, with ocular involvement                                    248190   AR

  **ATP1A1**                                                                                                                             ATPase Na+/K+ transporting subunit alpha 1                                    182310    Charcot-Marie-Tooth disease, axonal, type 2DD                                       618036   AD

  Hypomagnesemia, seizures, and mental retardation 2                                618314                                               AD                                                                                                                                                                                   

  **HNF1B**                                                                         HNF2                                                 HNF1 homeobox B                                                               189907    Diabetes mellitus, noninsulin-dependent                                             125853   AD

  Renal cysts and diabetes syndrome                                                 137920                                               AD                                                                                                                                                                                   

  KCNA1                                                                             MK1, MOUSE, HOMOLOG OF KV1.1                         Potassium voltage-gated channel subfamily A member 1                          176260    Episodic ataxia/myokymia syndrome                                                   160120   AD

  Autosomal dominant hypomagnesemia                                                 No MIM                                               AD                                                                                                                                                                                   

  **NR3C2**                                                                         MLR; MCR; MR ALDOSTERONE RECEPTOR                    Nuclear receptor subfamily 3 group C member 2                                 600983    Hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy       605115   AD (gain of function p.Ser810Leu)

  Pseudohypoaldosteronism type I, autosomal dominant                                177735                                               AD                                                                                                                                                                                   

  **WNK4**                                                                          PRKWNK4                                              WNK lysine deficient protein kinase 4                                         601844    Pseudohypoaldosteronism, type IIB                                                   614491   AD

  WNK1                                                                              PSK PRKWNK1 \_ KDP KIAA0344                          WNK lysine deficient protein kinase 1                                         605232    Neuropathy, hereditary sensory and autonomic, type II                               201300   AR

  Pseudohypoaldosteronism, type IIC                                                 614492                                               AD                                                                                                                                                                                   

  **KLHL3**                                                                         KELCH-LIKE 3                                         Kelch like family member 3                                                    605775    Pseudohypoaldosteronism, type IID                                                   614495   AD, AR

  **CASR**                                                                          PARATHYROID CA(2+)-SENSING RECEPTOR 1; PCAR1         Calcium sensing receptor                                                      601199    Hyperparathyroidism, neonatal                                                       239200   AD, AR

  Hypocalcemia, autosomal dominant                                                  601198                                               AD                                                                                                                                                                                   

  Hypocalcemia, autosomal dominant, with Bartter syndrome                           601198                                               AD                                                                                                                                                                                   

  Hypocalciuric hypercalcemia, type I                                               145980                                               AD                                                                                                                                                                                   

  {Epilepsy idiopathic generalized, susceptibility to, 8}                           612899                                                                                                                                                                                                                                    

  **GNA11**                                                                         GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-11         G protein subunit alpha 11                                                    139313    Hypocalcemia, autosomal dominant 2                                                  615361   AD

  Hypocalciuric hypercalcemia, type II                                              145981                                               AD                                                                                                                                                                                   

  **AP2S1**                                                                         CLAPS2, AP17                                         Adaptor related protein complex 2 sigma 1 subunit                             602242    Familial hypocalciuric hypercalcemia type III                                       600740   AD

  **CYP24A1**                                                                       CYTOCHROME P450, SUBFAMILY XXIV;                     Cytochrome P450 family 24 subfamily A member 1                                126065    Hypercalcemia, infantile, 1                                                         143880   AR

  SLC34A1 \*                                                                        NaPiIIa                                              Solute carrier family 34 (type II sodium/phosphate cotransporter), member 1   182309    ?Fanconi renotubular syndrome 2                                                     613388   AR

  Hypercalcemia, infantile, 2                                                       616963                                               AR                                                                                                                                                                                   

  Nephrolithiasis/osteoporosis, hypophosphatemic, 1                                 612286                                               AD                                                                                                                                                                                   

  SLC34A3 \*                                                                        NaPiIIc                                              Solute Carrier Family 34 Member 3                                             609826    Hypophosphatemic rickets with hypercalciuria                                        241530   AR

  CLDN10                                                                            OSPL\                                                Claudin 10                                                                    617579    HELIX syndrome\                                                                     617671   AR
                                                                                    CPETRL3                                                                                                                                      (anhidrosis, heat intolerance, renal sodium chloride wasting, mild renal failure)            

  **UMOD**                                                                          Tamm-Horsfall Glycoprotein; THP; THGP                Uromodulin                                                                    191845    Glomerulocystic kidney disease with hyperuricemia and isosthenuria                  609886   AD

  Hyperuricemic nephropathy, familial juvenile 1                                    162000                                               AD                                                                                                                                                                                   

  Medullary cystic kidney disease 2                                                 603860                                               AD                                                                                                                                                                                   

  **Collecting Duct (CD) \*\***                                                                                                                                                                                                                                                                                               

  **ATP6V0A4**                                                                      ATP6N1B\                                             ATPase H+ transporting V0 subunit a4                                          605239    Distal Renal Tubular Acidosis, Recessive                                            602722   AR
                                                                                    ATP6N2\                                                                                                                                                                                                                                   
                                                                                    VPP2                                                                                                                                                                                                                                      

  **ATP6V1B1**                                                                      ATP6B1\                                              ATPase H+ transporting V1 subunit B1                                          192132    Renal tubular acidosis with deafness                                                267300   AR
                                                                                    VPP3                                                                                                                                                                                                                                      

  **SLC4A1**                                                                        BND3, AE1                                            Solute carrier family 4 (anion exchanger), member 1                           109270    Cryohydrocytosis                                                                    185020   AD

  Ovalocytosis, SA type                                                             166900                                               AD                                                                                                                                                                                   

  Renal tubular acidosis, distal, AD                                                179800                                               AD                                                                                                                                                                                   

  Renal tubular acidosis, distal, AR                                                611590                                               AR                                                                                                                                                                                   

  Spherocytosis, type 4                                                             612653                                               AD                                                                                                                                                                                   

  **SLC4A4**                                                                        NBC1                                                 Solute carrier family 4 (sodium bicarbonate cotransporter), member 4          603345    Renal tubular acidosis, proximal, with ocular abnormalities                         604278   AR

  **CA2**                                                                                                                                Carbonic anhydrase 2                                                          611492    Osteopetrosis, autosomal recessive 3, with renal tubular acidosis                   259730   AR

  **AQP2**                                                                          AQUAPORIN-CD                                         Aquaporin 2                                                                   107777    Nephrogenic diabetes insipidus                                                      125800   AD AR

  **AVPR2**                                                                         ADHRV2R                                              Arginine vasopressin receptor 2                                               300538    Diabetes insipidus, nephrogenic                                                     304800   XLR

  Nephrogenic syndrome of inappropriate antidiuresis                                300539                                               XLR                                                                                                                                                                                  

  **SCNN1A**                                                                        SCNEA; SCNN1                                         Sodium channel epithelial 1 alpha subunit                                     600228    ?Liddle syndrome 3                                                                  618126   AD

  Bronchiectasis with or without elevated sweat chloride 2                          613021                                               AD                                                                                                                                                                                   

  Pseudohypoaldosteronism, type I                                                   234350                                               AR                                                                                                                                                                                   

  **SCNN1B**                                                                        SCNEB                                                Sodium channel epithelial 1 beta subunit                                      600760    Bronchiectasis with or without elevated sweat chloride 1                            211400   AD

  Liddle syndrome 1                                                                 177200                                               AD                                                                                                                                                                                   

  Pseudohypoaldosteronism, type I                                                   264350                                               AR                                                                                                                                                                                   

  **SCNN1G**                                                                        SCNEG                                                Sodium channel epithelial 1 gamma subunit                                     600761    Bronchiectasis with or without elevated sweat chloride 3                            613071   AD

  Liddle syndrome 2                                                                 618114                                               AD                                                                                                                                                                                   

  Pseudohypoaldosteronism, type I                                                   264350                                               AR                                                                                                                                                                                   

  **CUL3**                                                                                                                               Cullin 3                                                                      603136    Pseudohypoaldosteronism, type IIE                                                   614496   AD

  GNAS                                                                              GNAS1                                                GNAS complex locus                                                            139320    McCune-Albright syndrome, somatic,                                                  174800   mosaic

  Osseous heteroplasia, progressive                                                 166350                                               AD                                                                                                                                                                                   

  Pseudohypoparathyroidism Ia/Ib/Ic                                                 103580/603233/612462                                 AD                                                                                                                                                                                   

  Pseudopseudohypoparathyroidism                                                    612463                                               AD                                                                                                                                                                                   

  SLC20A2                                                                           PIT2                                                 Solute carrier family 20 (phosphate transporter), member 2                    158378    Basal ganglia calcification, idiopathic, 1                                          213600   AD

  Mutations found in renal patients but unclear phenotype                                                                                                                                                                                                                                                                     

  WDR72                                                                             WD REPEAT-CONTAINING PROTEIN 72                      WD repeat domain 72                                                           613214    Amelogenesis imperfecta, type IIA3                                                  613211   AR
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AR: autosomal recessive; AD: autosomal dominant; XLR: X-linked recessive; \* these genes are on the 'Red' list as they are also part of other panels. \*\* the segments are indicated based on their clinical significance and not necessarily as the only regions where the corresponding genes are expressed. The genes shown in bold are included in the 'Green' List of the Renal Tubulopathy Panel. Note: the rest of the genes are classified as 'Amber' or 'Red' based on a reduced number of reported cases or insufficient experimental evidence. The list corresponds to the PanelApp version 2.3 (<https://panelapp.genomicsengland.co.uk/panels/292/>; accessed 27/02/2020). Two AD variants of renal Fanconi syndromes, FRTS1 and FRTS3, are linked to genes involved in tubular cell metabolism, thus underlying the importance of energy supply for the proper functioning of transport mechanisms \[[@B27-genes-11-00277],[@B47-genes-11-00277],[@B49-genes-11-00277]\].
